| |
NewswireToday - /newswire/ -
Waltham, MA, United States, 11/28/2007 - Genedata announces agreement with the National Center for Toxicological Research of the U.S. Food and Drug Administration for the company’s Genedata Expressionist platform.
|
| |
Genedata, a leading provider of in silico solutions for the pharmaceutical and life sciences industries, today announced an agreement with the National Center for Toxicological Research of the U.S. Food and Drug Administration for the company’s Genedata Expressionist® biomarker discovery platform.
Genedata Expressionist is a modular computational platform for biomarker discovery that integrates transcriptomics, proteomics and metabolomics data within a single enterprise software system. With sophisticated high-throughput data processing and automated workflows for quality assessment, statistical analysis and interpretation functionalities, the platform provides a single-point-of-access for all experimental data, including sample information, raw and pre-processed data, analysis results and documentation with reports.
Weida Tong, Director of the Center for Toxicoinformatics at the U.S. Food and Drug Administration (FDA), said, “Given the vast quantities and varied sources of microarray data for the voluntary genomics data submission (VGDS) program, it is vital that my team have the most effective set of tools available to assay the data quality of submitted results. The automated quality assurance tools available in Expressionist will enable us to ensure reproducible and reliable results and to provide quantitative feedback where data quality is in question.”
Dr. Jens Hoefkens, Managing Director of Genedata, said, “We are delighted that the FDA has chosen Expressionist to ensure that reviewers of our customers` data at the FDA can use the same suite of tools and applications to identify markers based on rigorous quality control standards.”
|
communications[.]genedata.com 
